Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-anti-HER2 VHH1 PET in brain metastases
2024-513997-23-00Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Oct 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [68Ga]Ga-NOTA-ABSCINT-HER2 in brain metastases and cancer, sponsored by UZ Brussel. Primary endpoints: Visual tumor targeting in brain metastases and Quantitative tumor uptake in brain metastases (SUV). Started Oct 2017; status: completed.
02
Drugs
[68Ga]Ga-NOTA-ABSCINT-HER2
03
Conditions
brain metastasescancer
Beyond the preview
Go deeper on 2024-513997-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513997-23-00.